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RESUMO – Introdução: O tratamento dos carcinomas basocelulares é maioritariamente cirúrgico, sobretudo por cirurgia com 
avaliação histopatológica pós-operatória da margem (cirurgia convencional), mas os dados a longo-prazo relativos a recidiva de 
acordo com o resultado histológico da margem (excisão completa versus excisão incompleta, mantida em follow-up) são limita-
dos. Métodos: Estudo coorte retrospetivo dos carcinomas basocelulares tratados por cirurgia convencional e por diferentes espe-
cialidades médico-cirúrgicas num centro terciário, entre 2008 e 2014. Realizou-se uma análise multivariada com uma regressão 
de Cox, estratificada pelo resultado da avaliação histológica da margem (excisão completa/incompleta) e ajustada a várias va-
riáveis recolhidas. Resultados: Um total de 2876 carcinomas basocelulares foram identificados, dos quais 2306 [2100 primários, 
206 recidivantes (primeira recidiva)] foram considerados elegíveis para análise. Nos 5 anos de follow-up, verificaram-se 80 (4%) 
recidivas entre os 1959 tumores completamente excisados (16/1000 casos-ano), contrastando com 83 (23,9%) recidivas em 347 
excisões incompletas (100/1000 casos-ano). Foi realizada uma análise de sobrevida ajustada. No modelo final, ajustado, multi-
variado, foi identificada associação entre recidiva e intervenção cirúrgica a tumores recorrentes [hazard ratio (HR) ajustado 2,20 
(Intervalo confiança (IC) 95%, 1,26-3,84),  p=0,006], cirurgia com diagnóstico pré-operatório errado/ausência de realização de 
biópsia prévia [HR ajustado 2,75 (IC 95%, 1,68-4,5), p<0,001], tratamento prévio a 2012 [HR ajustado 1,47 (CI 95%,  1,06-
2,05),  p<0,021] e cirurgia em localização de alto-risco, de acordo com a classificação NCCN [HR ajustado 2,18 (IC 95%, 1,08-
4,40), p<0,030]. Por localização anatómica específica, a probabilidade de recidiva a longo-prazo é especialmente elevada se a 
cirurgia for na pirâmide nasal [HR ajustado 3,18 (IC 95%, 1,71-5,87), p<0,001] ou nas pálpebras [HR ajustado 3,08 (CI 95%, 
1,32-7,17), p=0,009]. Verificou-se também uma tendência para maior recidiva nos subtipos histológicos agressivos [HR ajustado 
1,43 (IC 95%, 0,99-2,07), p<0,058]. Conclusão: Os carcinomas basocelulares recorrentes, independentemente da localização, 
e os carcinomas basocelulares primários em localizações de alto-risco da face, particularmente na pirâmide nasal e nas pálpe-
bras, determinam um risco de recidiva superior e independente a longo-prazo, mesmo nas excisões “completas”. Por outro lado, 
as estratégias wait-and-see nos carcinomas basocelulares incompletamente excisados devem ponderar o risco de recidiva aos 5 
anos (1 in 10 lesões). 
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Five-Year Risk of Basal Cell Carcinoma Recurrence 
After a Conventional Surgical Excision 
ABSTRACT – Introduction: Basal cell carcinomas are mostly treated surgically, mostly by surgery with postoperative histopathologic 
margin evaluation (“conventional surgery”), but large long-term data regarding recurrence by completeness of excisions is 
limited. Methods: Retrospective cohort study of basal cell carcinomas treated by conventional surgery at different medical 
specialties in a large tertiary centre, between 2008 and 2014. Survival analysis with a Cox proportional-hazards was performed, 
stratified by completeness of excision (complete excision/incomplete excision) and adjusted to several potentially confounding 
covariates. Results: A total of 2876 basal cell carcinomas were identified, of which 2306 (2100 primary, 206 recurrent) were 
considered eligible for analysis. During the 5-years of follow-up, there were 80 (4%) recurrences among 1980 complete excisions 
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Basal cell carcinoma (BCC) is an exceedingly common 
malignancy worldwide.1 In spite of being almost devoid of me-
tastatic capacity, BCC behaves as a locally destructive tumor, 
ultimately causing functional and cosmetic impairment as well 
as significant economic burden.2,3 At present, surgery remains 
the preferred treatment for most BCC, mostly performed with 
postoperative histopathological margin control (“conventional 
surgery”). Mohs micrographic surgery (MMS) is an alternative 
which is regarded as the optimal treatment for high-risk BCCs, 
allowing full margin control.4 Nevertheless, it is time-consu-
ming and requires facilities and trained personnel, which are 
not widespread in some countries. Thus judicious selection of 
the lesions with the highest risk of recurrence to be intervened 
by MMS is a reasonable use of the technique. 
In conventional surgery, regardless of the completeness 
of excision, a significant proportion (5.9%) of tumors will still 
recur,5 leading to unwarranted morbidity and costs. On the 
other hand, incomplete excisions is commonly regarded as 
a surrogate for recurrence, but some physicians advocate 
a careful long-term follow-up instead of immediate surgical 
re-intervention, due to a degree of uncertainty regarding re-
currences in incompletely excised lesions.6 
The aim of this study is to identify the rate and the risk 
factors that may preoperatively foresee recurrences for basal 
cell carcinomas treated with conventional surgery, in both 
complete and incomplete excisions. 
METHODS
Study design and data retrieval 
We performed a retrospective cohort study in one of the 
largest university-based tertiary medical institutions in Por-
tugal. All electronic health records and pathology reports 
of surgically-treated BCCs between January 2008 and De-
cember 2014 were retrieved and collected through database 
searching tools hosted at the institution. 
Study population 
We included adult patients with at least one BCC subjec-
ted to surgery of curative intent with postoperative histopa-
thological evaluation (“conventional surgery”) in any surgical 
department of the hospital. Recorded variables included pa-
tient age (dichotomized into <80 and ≥80 years), gender, 
immune status, department of the treating physician (Der-
matology, Plastic and Reconstructive Surgery (PRS), Other), 
year of surgical treatment (dichotomized into 2008-2011 
and 2012-2014), tumor status (primary vs recurrent), tu-
mour size (<1 cm, 1-3 cm, >3 cm), tumor location [evalua-
ted by the specific anatomic location: forehead, nose, ears, 
lips, upper and lower eyelids, eyebrows, cheeks, jawline and 
chin, preauricular and temporal area and trunk and extre-
mities; and by the latest National Comprehensive Cancer 
Network (NCCN) risk stratification framework (7): high-risk 
area (H area), medium-risk area (M area) and low-risk area 
(L area)], histopathological BCC subtype (nodular subtype, 
superficial/other non-aggressive subtypes, aggressive sub-
types), completeness of excision (as defined by the absence 
of residual neoplastic tissue at the lateral or deep margins, 
while an incomplete excision is characterized by residual 
tumor in either of the margins; of note, incompletely excised 
tumors included only those which were chosen to follow-up 
instead of immediate re-excision or in which the re-excision 
did also not achieved clear margins), defect closure tech-
nique (primary closure, second intention, skin flap, full or 
split thickness skin graft) and time until recurrence or end 
of follow-up (60 months). Exclusion criteria included BCCs 
treated with non-surgical treatments (imiquimod, 5-fluorou-
racil) or minimally invasive techniques (curettage and elec-
trodessication, laser therapy, photodynamic therapy). MMS is 
not currently performed in our institution. A flowchart of the 
selection process is presented in Fig. 1.
Statistical analysis
Baseline data were reported as n (%) and mean SD, or 
medians and interquartile range according to the distribu-
tion. We used a chi-square test to compare the baseline 
categorical variables between the recurrence and non-recur-
rence groups. To characterize the variables associated with 
local recurrence after a conventional surgical treatment, a 
univariate and adjusted Cox proportional-hazards model 
stratified by the completeness of excision (complete vs in-
complete) was constructed for recurrences occurring for 60 
(16/1000 cases-year) and 83 (23.9%) recurrences among 348 incomplete excisions (100/1000 cases-year). Survival analysis 
was performed with multivariable adjustment. In the final adjusted model, we identified an association between relapse and 
re-intervention on recurrent tumors [adjusted Hazard Ratio (HR) 2.20 (95% Confidence interval (IC), 1.26-3.84), p=0.006], a 
wrong preoperative clinical diagnosis/surgery devoid of preoperative biopsy [adjusted HR 2.75 (95% CI, 1.68-4.5), p<0.001], 
treatment prior to 2012 [adjusted HR 1.47 (95% IC, 1.06-2.05), p<0.021] and surgery on a high-risk location, accordingly 
to the NCCN stratification [adjusted HR 2.18 (95% CI, 1.08-4.40), p<0.030]. By specific anatomic location, the likelihood of 
recurrence was especially high in the nose [adjusted HR 3.18 (95% CI 1.71-5.87),  p<0.001] and eyelids [adjusted HR 3.08 (95% 
CI, 1.32-7.17),  p=0.009]. There was also a trend towards higher recurrence in aggressive histological subtypes [adjusted HR 
1.43 (95% CI 0.99-2.07),  p<0.058]. Conclusion: Recurrent basal cell carcinomas, regardless of location, and primary basal 
cell carcinomas on high-risk locations of the face, especially on the eyelids and nose, should be considered to have a higher and 
independent likelihood of recurrence, even on “complete excisions” evaluated by histopathology. On the other hand, wait-and-
see approaches in incompletely excised BCCs should be considered against a significant 5-year risk of relapse (1 in 10 lesions). 
KEYWORDS – Carcinoma, Basal Cell; Dermatologic Surgical Procedures; Skin Neoplasms.
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months after surgery. Patients were censored at the date of 
histological confirmation of a recurrence or at the date of the 
last follow-up visit. Crude hazards ratio (HR) at a 95% Con-
fidence Interval (95% CI) were calculated and reported. For 
all tumor characteristics, the category with higher represen-
tation was selected as reference. All covariates considered 
important according to their clinical or statistical significan-
ce were included in the multivariate analysis. A significance 
level of 0.05 and a confidence interval of 0.95 was conside-
red significant. All statistical analyses were performed with 
StataCorp. 2017. Stata Statistical Software: Release 15. Col-
lege Station, TX: StataCorp LLC.
RESULTS
Baseline characteristics and non-independent 
associations
A total of 2876 BCCs were identified in the electronic 
healthcare database, of which 2306 BCCs [2100 primary, 
206 recurrent (first recurrence)] were eligible after complying 
with both the inclusion and exclusion criteria (see detailed 
flowchart in Fig. 1). The baseline clinical, histological and 
tumoral characteristics were collected and several, albeit not-
-independent, associations were observed (shown in Table 
1). As incomplete excisions are often regarded as a surro-
gate for long-term recurrence, we stratified the lesions into 
two groups – completely excised and incompletely excised 
tumors (Table 2, and for visual comparison between crude 
recurrences in both groups, see Fig. 2). During the 60 mon-
ths of follow-up (total person-years: 5871.4) there were 80 
(4%) recurrences among the 1959 complete excisions (16 
cases per 1000 patient-years), which compares with the 83 
(23.9%) recurrences among the 347 incomplete excisions 
(100 cases per 1000 patient-years).  
Survival analysis
In the crude analysis, recurrences were associated with 
the type of diagnosis, the treating department, the histologi-
cal subtype, the NCCN and anatomic risk locations and clo-
sure with flaps. Neither age, gender, immune status, year of 
surgery or tumor size met statistical significance in the unad-
justed analysis. 
After multivariable adjustment, there was an association 
between relapse and recurrent tumors [adjusted HR 2.02 
(1.40-2.93), p=<0.001. Fig. 3] tumors in which the diag-
nosis was made by excisional (therapeutic) biopsy without 
a preoperative biopsy [adjusted HR 1.75 (95% CI, 1.25-
2.45), p<0.001], surgical treatment prior to 2012 [adjusted 
HR 1.47 (95% CI, 1.06-2.05), p<0.021] and surgery on a 
NCCN high-risk location [adjusted HR 2.74 (95% CI, 1.25-
4.90), p<0.001]. After adjustment for specific anatomical 
regions (instead of the more general NCCN risk locations. 
Fig. 4), there was a strong association with recurrence after 
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Figure 1 - Flowchart of patient selection. 
Figure 2 - Recurrence probabilities of basal cell carcinomas, accor-
ding to the completeness of excision. 
Figure 3 - Recurrence probabilities of basal cell carcinomas, accor-
ding to the status of the tumor (primary or recurrent). 
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Table 1 - Study groups baseline clinicopathological characteristics. Stratification by the excision status (complete 






(N = 80, 4.10%)
No recurrence








< 80 years 1229 47 (2.40) 1182 (60.34) 0.452 217 60 (17.29) 157 (45.24) 0.035
≥ 80 years 730 33 (1.68) 697 (35.58) 130 23 (6.63) 107 (30.84)
Gender
Male 1078 52 (2.65) 1026 (52.37) 0.067 191 46 (13.26) 145 (41.79) 0.937
Female 881 28 (1.53) 853 (43.54) 156 37 (10.66) 119 (34.29)
Immunosuppression
No 1850 76 (3.88) 1774 (90.56) 0.822 332 74 (31.55) 258 (74.35) 0.001
Yes 109 4 (0.2) 105 (5.36) 15 6 (1.73) 9 (2.59)
Year of surgery
2008-2011 678 40 (2.04) 638 (32.57) 0.003 120 36 (10.37) 84 (24.21) 0.054
2012-2014 1281 40 (2.04) 1241 (63.35) 227 47 (13.54) 80 (51.87)
Treating department
Dermatology 1760 69 (3.52) 1691 (86.32) 0.391 292 71 (20.46) 221 (63.69) 0.304
PRS 165 10 (0.51) 155 (7.91) 45 8 (2.31) 37 (10.66)
Other 34 1 (0.05) 33 (1.68) 10 4 (1.15) 6 (1.73)
Type of diagnosis
Clinical 1768 39 (1.99) 1486 (75.86) <0.001 243 49 (14.12) 194 (55.91) 0.012
Histological 538 41 (2.09) 393 (20.06) 104 34 (9.80) 70 (20.17)
Histological subtype
Nodular 1564 60 (3.06) 1504 (76.77) 0.188 210 45 (12.97) 165 (47.55) 0.157
Superficial 154 5 (0.26) 149 (7.61) 28 5 (6.63) 23 (1.44)
Aggressive 241 15 (0.77) 226 (11.54) 109 33 (9.51) 76 (21.90)
NCCN risk locations
H area 761 43(2.19) 718 (36.65) 0.007 200 55 (15.85) 145 (41.79) 0.002
M area 613 24 (1.23) 589 (30.07) 86 24 (6.92) 62 (17.87)




585 13 (0.66) 572 (29.20) 0.012 61 4 (1.15) 57 (16.43) 0.029
Nose 345 21 (16.24) 324 (1.07) 108 34 (9.80) 64 (21.33)
Cheeks 192 7 (0.36) 185 (9.44) 34 11 (3.17) 23 (6.63)
Forehead 147 7 (0.36) 140 (7.15) 26 8 (2.31) 18 (5.19)
Preauricular 125 7 (0.36) 118 (6.02) 27 8 (2.31) 19 (5.48)
Temple 126 6 (0.21) 120 (6.13) 10 2 (0.58) 8 (2.31)
Eyelids 80 8 (0.41) 72 (3.62) 22 5 (4.90) 17 (1.44)
Other 359 11 (0.56) 348 (17.76) 59 11 (3.17) 48 (13.84)
Tumour size
<1 cm 318 14 (0.71) 304 (15.52) 0.545 100 29 (8.46) 71 (20.46) 0.250
1-3 cm 1420 60 (3.06) 1360 (69.42) 223 47 (13.54) 176 (50.72)
>3 cm 221 6 (0.31) 215 (10.97) 24 7 (2.02) 17 (4.90)
Recurrent BCC
No 1815 59 (3.01) 1756 (89.64) <0.001 285 56 (16.14) 229 (65.99) <0.001
Yes 144 21 (1.27) 123 (6.28) 62 27 (7.78) 35 (10.09)
Defect closure technique
Primary closure 1607 57 (2.91) 1550 (79.12) <0.001 5 63 (18.16) 199 (57.35) 0.654
2nd healing 
intention
6 2 (0.10) 4 (0.20) 262 0 (0.00) 5 (1.44)
Flap 196 13 (9.34) 183 (0.66) 44 11 (3.17) 33 (9.51)
Skin graft 150 8 (0.41) 142 (7.25) 36 9 (2.59) 27 (7.28)
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Table 2 - Univariate and multivariate analysis of clinicopathological risk factors for recurrence. Stratification by 





(by NCCN risk areas)
Multivariate analysis
(by anatomic location)
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Age at treatment
<80 years 1446 1 [Reference] - - - - -
≥ 80 years 860 1.17 (0.84-1.61) 0.353 - - - -
Gender
Male 1037 1 [Reference] - - - - -
Female 1269 1.07 (0.79-1.47) 0.634 - - - -
Immunosuppression
No 2182 1 [Reference] - - - - -
Yes 124 .1.53 (0.86-2.74) 0.148 - - - -
Year of surgery
2008-2011 798 1.37 (0.99-1.86) 0.051 1.47 (1.06-2.05) 0.021 1.47 (1.07-2.04) 0.019
2012-2014 1508 1 [Reference] - 1 [Reference] - 1 [Reference] -
Treating department
Dermatology 2052 1 [Reference] - 1 [Reference] - 1 [Reference] -
PRS 210 2.46 (1.26-4.80) 0.008 1.31 (0.75- 2.78) 0.348 1.30 (0.74-2.51) 0.358
Other 44 1.36 (0.19-9.83) 0.760 2.43 (0.97-6.12) 0.059 2.32 (0.82-6.60) 0.113
Type of diagnosis
Clinical 1768 1 [Reference] - 1 [Reference] - 1 [Reference] -
Histological 538 2.30 (1.69-3.14) <0.001 1.75 (1.25-2.45) 0.001 1.78 (1.30-2.50) 0.001
Histological subtype
Nodular 1774 1 [Reference] - 1 [Reference] - 1 [Reference] -
Superficial and other 
non-aggressive 
182 1.37 (0.71-2.69) 0.340  1. 36 (0.66-2.80) 0.410  1. 38 (0.68-2.88) 0.377
Aggressive subtypes 350 2.44 (1.24-4.85) 0.010 1.43 (0.99-2.07) 0.058 1.45 (0.99-2.11) 0.052
NCCN risk locations
High-risk area 961 2.57 (1.39-4.77) 0.003 2.74 (1.25-4.90) 0.001 - -
Medium-risk area 699 1.66 (0.85-3.26) 0.141 2.39 (1.30-4.37) 0.005 - -
Low-risk area 646 [Reference] - 1 [Reference] - -
Anatomic area
Trunk and extremities 646 1 [Reference] - - - 1 [Reference] -
Nose 453 3.47 (2.01-6.01) <0.001 - - 3.18 (1.71-5.87) <0.001
Cheeks 226 2.67 (1.37-5.17) 0.004 - - 2.99 (1.45-6.17) 0.003
Forehead 173 3.21 (1.60-6.44) 0.001 - - 2.86 (1.37-6.00) 0.005
Preauricular 152 2.98 (0.93-5.81) 0.073 - - 2.93 (1.39-6.16) 0.005
Temple 136 .2.16 (0.93-4.99) 0.074 - - 2.01 (0.63-4.91) 0.122
Eyelids 102 4.07 (1.97-8.43) <0.001 - - 3.08 (1.32-7.17) 0.009
Other 418 1.78 (0.94-3.41) 0.079 - - 1.65 (0.83-3.31) 0.156
Tumour size
<1 cm 318 1.16 (0.81-1.66) 0.421 1.13 (0.68-1.54) 0.509 1.17 (0.81-1.70) 0.411
1-3 cm 1420 1 [Reference] - 1 [Reference] 1 [Reference]
>3 cm 221 1.03 (0.58-1.84) 0.908 1.03 (0.59-1.88) 0.931 1.14 (0.60-2.14) 0.688
Recurrent BCC
No 2100 1 [Reference] - 1 [Reference] - 1 [Reference] -
Yes 206 2.84 (2.01-4.06) <0.001 2.02 (1.40-2.93) <0.001 1.99 (1.37-2.88) <0.001
Defect closure technique
Primary closure 1869 1 [Reference] - - - - -
2nd healing intention 11 1.51 (0.37-6.15) 0.561 - - - -
Flap 240 1.88 (1.21-2.92) 0.005 - - - -
Skin graft 186 1.27 (0.76-2.12) 0.349 - - - -
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excisions on the nose [adjusted HR 3.18 (95% CI 1.71-5.87), 
p<0.001] and the eyelids [adjusted HR 3.08 (95% CI, 1.32-
7.17), p=0.009] followed by the cheeks [adjusted HR 2.99 
(95% CI, 1.45-6.17), p=0.003] the preauricular region [ad-
justed HR 2.93 (95% CI, 1.37-6.00), p=0.005], and the fo-
rehead [adjusted HR 2.86 (95% CI, 0.92-4.47), p=0.081]. 
There was also a trend towards a higher risk of recurrence 
in aggressive histological subtypes [adjusted HR 1.43 (95% 
CI 0.99-2.07), p<0.058]. Neither the treating department or 
the type of defect closure achieved statistical significance in 
the final adjusted model.
DISCUSSION
To the best of our knowledge, we present one of the lar-
gest multidisciplinary real-world studies where predictive 
factors for BCC long-term recurrence were evaluated. This 
knowledge is of paramount importance to improve surgical 
planning and to provide evidence-based support to prioritize 
some tumors (of higher risk) to more radical and/or effective 
treatments, such as MMS, instead of others with lower long-
-term risk of relapse. 
After adjusting for several confounders, we found a po-
sitive association between neoplastic recurrence and preo-
perative misdiagnosis, location in a NCCN high-risk area 
(especially the nose and eyelids), recurrent BCCs (re-ope-
rated by conventional surgery) and surgical treatment prior 
to 2012. Likewise, we observed a trend towards statistical 
significance in aggressive histologic subtypes (non-superfi-
cial and non-nodular). While the lack of statistical signifi-
cance in the latter may be explained by the low caseload 
of aggressive subtypes, it may in fact portend a diminished 
effect in the long-term risk of recurrence determined by the 
histologic subtype after a “complete” excision when compa-
red to the aforementioned covariates. 
In our analysis, we found that tumors on the nose [adjus-
ted HR 3.18 (95% CI 1.71-5.87), p<0.001], followed clo-
sely by the eyelids [adjusted HR 3.08 (95% CI, 1.32-7.17), 
p=0.009] had the higher likelihood of relapse in the long-
-term. To achieve easier defect closures in these are sensiti-
ve areas, surgeons are more likely to try to preserve lateral 
tissue compared with other anatomical areas where more 
tissue can be safely removed.5 This probably contributes to 
explain the higher long-term risk of relapse, even after mul-
tivariate adjustment. It should be reminded that it is the re-
construction technique that should be tailored to the size of 
the excision defect, and not the contrary, as the main objec-
tive of the surgery is to remove the tumour and its subclinical 
spread completely.
The only randomized controlled trial with long-term 
follow-up comparing MMS and conventional surgery to ma-
nage high-risk facial BCC was few years ago published by 
van Loo et al.8 As fewer recurrences were found with MMS, 
the authors suggested that high-risk facial primary and re-
current BCCs should be the main indications for this te-
chnique.8 Our study is in complete agreement with these 
recommendations. Nevertheless, the decision to referral or 
intervention by standard (conventional) excision should rely 
on best judgement of experienced physicians in dermato-
-oncological care, which should take into account all of the 
patient’s clinical and cutaneous malignancy characteristics. 
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Figure 4 - Recurrence probabilities of basal cell carcinomas, according to their specific anatomic location. 
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For example, those with limited life expectancy or in poor 
health can probably be managed by conventional surgery or 
other minimally invasive procedures instead of MMS.9 This 
may aid to relieve pressure on the awaiting lists of Mohs 
surgery facilities. 
Larger (>3 cm) tumoral dimensions failed to be of prog-
nostic significance to recurrence in the adjusted model. Se-
veral explanations could be gathered. First, larger BCCs are 
usually clinically easier to diagnose compared to smaller 
lesions. Secondly, they are more prone to be biopsied (to 
avoid unnecessary mutilating excisions) than smaller lesions 
amenable to primary closure. Lastly, “scarier” tumoral mas-
ses will instigate surgeons into more radical excisions (with 
larger peripheral margins). 
A final remark is made on the controversy regarding 
recurrence risk after an incomplete excision. Although pre-
sence of residual tumour in the histopathological evaluation 
(“incomplete excision”) is considered a surrogate for recur-
rence in most cancers, in BCC management this association 
is not clear-cut. In fact, not all incompletely excised tumors 
recur.10 Additionally, residual neoplastic tissue is found in 
only 36%–54% of the immediate re-excision specimens.6,11,12 
Potential, albeit speculative, explanations are the clearance 
of residual neoplastic cells by the hyperinflammatory wound 
repair, as well as the unclear histopathological definitions 
of “incomplete” versus “close” or “tangential” excisions in 
some of the published papers. Most importantly, a significant 
number of physicians often perform an expectant approa-
ch rather than immediate re-intervention in the presence 
of an incompletely excised BCC. In spite of this preference, 
our results demonstrate a remarkable clinical and statisti-
cal difference regarding the recurrence rate, as 1 in every 
10 incompletely excised tumors under follow-up will recur 
(5-year risk of 23.9%), contraposing to only 4% (80/1980) 
after a completely excised lesion. This outcome was similar 
to the recent Codazzi et al study.5 Expectant “wait-and-see” 
approaches should thus be considered with the present risk 
in mind. When the patient is deemed unfit for a new surgery 
local radiotherapy might be a good alternative to maintain a 
low-risk of recurrence in the long term.
Our study demonstrates several strengths, such its large 
sample size and data comprising different, independent de-
partments that perform cutaneous surgery at a large referral 
institution. Thus, our study best represents the BCCs real-life 
management in a tertiary setting. Nevertheless, it also has 
limitations. As in all observational studies, our retrospective 
design implies that some residual confounding, due to ei-
ther unmeasured or poorly measured covariates, cannot be 
excluded. Some factors, such as tumoral border definition 
and surgeon dependent-outcomes (technical experience and 
expertise), were impossible to acquire and analyse and thus 
were not included as a covariate in the model. Lastly, the 
follow-up ended at 60 months, which is insufficient to captu-
re ultra-late recurrences.13
In conclusion, in our large multidisciplinary single-cen-
tre study, recurrent BCCs and primary BCCs in high-risk 
locations, especially on the eyelids and nose, identify a 
higher risk cohort for long-term recurrence. On the other 
hand, wait-and-see approaches in incompletely excised 
BCCs should be considered against a significant 5-year risk 
of relapse (1 in 10 lesions).  
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